Frequency and spectrum of PIK3CA somatic mutations in breast cancer

PURPOSE: The therascreen PIK3CA mutation assay and the alpha-specific PI3K inhibitor alpelisib are FDA-approved for identifying and treating patients with advanced PIK3CA-mutated (PIK3CAmut) breast cancer (BC). However, it is currently unknown to what extend this assay detects most PIK3CA mutations...

Descripción completa

Detalles Bibliográficos
Autores principales: Martínez-Sáez, Olga, Chic, Nuria, Pascual, Tomás, Adamo, Barbara, Vidal, Maria, González-Farré, Blanca, Sanfeliu, Esther, Schettini, Francesco, Conte, Benedetta, Brasó-Maristany, Fara, Rodríguez, Adela, Martínez, Débora, Galván, Patricia, Rodríguez, Ana Belén, Martinez, Antonio, Muñoz, Montserrat, Prat, Aleix
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222307/
https://www.ncbi.nlm.nih.gov/pubmed/32404150
http://dx.doi.org/10.1186/s13058-020-01284-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222307/
https://www.ncbi.nlm.nih.gov/pubmed/32404150
http://dx.doi.org/10.1186/s13058-020-01284-9

Ejemplares similares